|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2005-9-27
|
|
pubmed:abstractText |
We performed a pilot study of combination chemotherapy with TS-1 and cisplatin for highly advanced gastric cancer. From June 2002, 12 patients with multiple liver metastases, carcinomatous lymphangitis or peritoneal dissemination, were enrolled in the study. TS-1 was administered at a daily dose on day 1-21 and an intermediate-dose of cisplatin (60 mg/m2) was administered on day 8. The combination was repeated in a 5-week cycle. The median administered cycles were three (one to eight). An objective response was obtained in 9 cases (75.0%) of primary sites and 6 cases of metastatic sites. No severe hematological toxicity occurred, and grade 3 stomatitis (in one case) and vomiting (in two cases) occurred as non-hematological toxicities. The improvement of clinical symptoms such as appetite loss and abdominal discomfort was obtained in 9 of 10 cases. The median survival time is 244 days. The TS-1/CDDP regimen had almost no survival benefits, but may induce relief of symptoms due to cancer and better quality of life.
|
|
pubmed:language |
jpn
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0385-0684
|
|
pubmed:author |
pubmed-author:FujimoriMototsuguM,
pubmed-author:FukuyamaYoshioY,
pubmed-author:HayasakaAkiraA,
pubmed-author:InkyoTakashiT,
pubmed-author:KomaYoshihiroY,
pubmed-author:NagashimaFumitakaF,
pubmed-author:OhbuMasamichiM,
pubmed-author:SaishoHiromitsuH,
pubmed-author:SakaiYujiY,
pubmed-author:SaotomeTakashiT,
pubmed-author:SatoTsunenobuT,
pubmed-author:ShimizuSatoshiS,
pubmed-author:TsuchiyaShinS,
pubmed-author:TsuyuguchiToshioT,
pubmed-author:YugetaHirokazuH
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
32
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1319-22
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16184932-Administration, Oral,
pubmed-meshheading:16184932-Adult,
pubmed-meshheading:16184932-Aged,
pubmed-meshheading:16184932-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16184932-Carcinoma, Signet Ring Cell,
pubmed-meshheading:16184932-Cisplatin,
pubmed-meshheading:16184932-Combined Modality Therapy,
pubmed-meshheading:16184932-Drug Administration Schedule,
pubmed-meshheading:16184932-Drug Combinations,
pubmed-meshheading:16184932-Female,
pubmed-meshheading:16184932-Humans,
pubmed-meshheading:16184932-Male,
pubmed-meshheading:16184932-Middle Aged,
pubmed-meshheading:16184932-Oxonic Acid,
pubmed-meshheading:16184932-Paclitaxel,
pubmed-meshheading:16184932-Pilot Projects,
pubmed-meshheading:16184932-Pyridines,
pubmed-meshheading:16184932-Quality of Life,
pubmed-meshheading:16184932-Stomach Neoplasms,
pubmed-meshheading:16184932-Tegafur
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
[A pilot study of TS-1+CDDP therapy for highly advanced stage IV gastric cancer].
|
|
pubmed:affiliation |
Division of Gasttroenterlogy. Chiba University.
|
|
pubmed:publicationType |
Journal Article,
English Abstract,
Case Reports
|
